Swiss Medtech represents the Swiss medical technology industry association with around 700 members.
Keystone / Gaetan Bally
Some two thirds of Swiss medtech companies support the new Switzerland-EU package. This is the result of a survey conducted by the opinion research institute JRC. Approval has also increased since the announcement of the US tariffs.
+Get the most important news from Switzerland in your inbox
According to the survey, over 70% of companies rate the package as important for their business and 80% as crucial for Switzerland as a medtech location. Furthermore, eight out of ten companies support the bilateral approach to date, according to the Swiss Medical Technology Association Swiss Medtech on Friday.
The decisive factors for this support are the free movement of persons and direct market access, according to the press release from the industry association, which commissioned the survey. Swiss Medtech sees this approval as a “clear mandate to support the Bilaterals III with commitment in the interests of the medtech sector”.
More
More
Syringes, scanners and implants: How US tariffs could affect medical device manufacturers
During the survey period, US President Trump announced the new tariffs on Swiss imports. The JRC concluded that support for the package increased even further after the tariff announcement. Before the announcement, approval was at 60%, afterwards at 68%, according to the industry association.
The opinion research institute surveyed all of Swiss Medtech’s approximately 800 members on the bilateral agreements between July 3 and August 11. According to the press release, the response rate was around 40%.
Translated from German by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into 0045nglish. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
